

**Enterprise P&T Meeting
Committee Meeting Minutes
July 29, 2024**

Voting Members Present

Christopher Antypas, PharmD	Donald Cooper, PharmD	Emily Kryger, PharmD	Christy Skibicki, MD
Michael Baer, MD	Tracey Davis, PharmD	Eric Peters, PharmD	Rani Whitfield, MD
David Batluck, DO	Rogers Elebra, PharmD	Andrew Peterson, PharmD	
Floyd (John) Brinley, MD	Fury Fecondo, PharmD	David Petkash, MD	
Robert Clifford, MD	Robert Hockmuth, MD	Jena Quinn, PharmD	

Excused Voting Members

Donald Beam, MD	Yavar Moghimi, MD		
Kirt Caton, MD	Michelle Murphy, PharmD		
Loretta Dumontet, MD	Wayne Weart, PharmD		
Lenaye Lawyer, MD			
Kelly Martin, PharmD			

Invited Guests Present

Bethany Baird, CPhT	Amanda Hunter, PharmD	Melissa Megrdochian, PharmD	Luke Stadler, PharmD
Linda Carreras, CPhT	Toks Kassim, PharmD	Sarah Pawlak, PharmD	Mali Thomas, CPhT
Patrick DeHoratius, PharmD	Lisa Kazakis	Alishia Richie, MD	Lauren Washington, CPhT
Natalie Dick, CPhT	Jeffrey Kreitman, PharmD	Ally Seitz, PharmD	Arlene Wiseman, PharmD
Rajneel Farley, PharmD	Lauren Megargell, PharmD	Ruth Smith, PharmD	

Issue	Discussion	Conclusion/Results	Action/ Person Responsible
1. Call to Order	The meeting was called to order at 6:03 PM EST. name Welcomed all external and internal participants.	Informational Only	Jeffrey Kreitman
2. Conflict of Interest Disclosure	No conflicts announced	Informational Only	Jeffrey Kreitman
4. Review and approval of April P&T and July Proxy Minutes		Committee approved as recommended: Motion: David Batluck Second: Don Cooper	Jeffrey Kreitman
5. Old Business			

6. New Business			
<p>[REDACTED]</p> <p>[REDACTED]</p>	<p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p>	<p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p>	<p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p>
<p>[REDACTED]</p>	<p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p>	<p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p>	<p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p>
Sleep Disorder Therapy	<p>PerformRx makes the following recommendation:</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>CHC:</p>	<p>Committee approved as recommended:</p> <p>Motion: Robert Hockmuth</p> <p>Second: Tracey Davis</p>	<p>PerformRx will update the criteria and formulary/PDL with any changes</p>

	<ul style="list-style-type: none"> Remove Lumryz from the policy as it is no longer rebatable under CMS regulation. 		
Lantidra	<p>PerformRx makes the following recommendation:</p> <p>█ █ [REDACTED] [REDACTED] [REDACTED] [REDACTED]</p> <p>█ █ [REDACTED] [REDACTED] [REDACTED] [REDACTED]</p> <p>█ █ [REDACTED] [REDACTED] [REDACTED] [REDACTED]</p> <p>█ █ [REDACTED] [REDACTED] [REDACTED] [REDACTED]</p>	<p>Committee approved as recommended:</p> <p>Motion: Robert Hockmuth Second: Tracey Davis</p>	<p>PerformRx will update the criteria and formulary/PDL with any changes</p>

	<p>██████████</p> <ul style="list-style-type: none"> ██████████ <p>██████████</p> <p>██████████ CHC:</p> <ul style="list-style-type: none"> Retire the Lantidra (donislecel) prior authorization criteria due to lack of utilization and the product is no longer rebatable under CMS regulation. <p>██████████</p> <ul style="list-style-type: none"> ██████████ 		
<p>████████████████████</p>	<p>████████████████████</p> <p>████████████████████</p> <p>██████████</p> <ul style="list-style-type: none"> ██████████ <p>██████████</p> <ul style="list-style-type: none"> ██████████ <p>██████████</p> <ul style="list-style-type: none"> ██████████ 	<p>████████████████████</p> <p>████████████████████</p> <p>████████████████████</p> <p>██████████</p>	<p>████████████████████</p> <p>████████████████████</p> <p>████████████████████</p> <p>████████████████████</p>

	<ul style="list-style-type: none"> █ [REDACTED] █ [REDACTED] █ [REDACTED] █ [REDACTED] █ [REDACTED] █ [REDACTED] █ [REDACTED] █ [REDACTED] █ [REDACTED] █ [REDACTED] █ [REDACTED] 		
Elevidys	<p>PerformRx makes the following recommendation:</p> <p>█ [REDACTED]</p> <ul style="list-style-type: none"> █ [REDACTED] █ [REDACTED] █ [REDACTED] █ [REDACTED] █ [REDACTED] █ [REDACTED] █ [REDACTED] <p>█ [REDACTED]</p> <ul style="list-style-type: none"> █ [REDACTED] █ [REDACTED] <p>█ [REDACTED]</p> <ul style="list-style-type: none"> █ [REDACTED] █ [REDACTED] █ [REDACTED] 	<p>Committee approved as recommended:</p> <p>Motion: Robert Hockmuth Second: Tracey Davis</p>	<p>PerformRx will update the criteria and formulary/PDL with any changes</p>

- [REDACTED]
[REDACTED]
- [REDACTED]
[REDACTED]
[REDACTED]

[REDACTED]

- [REDACTED]
[REDACTED]
[REDACTED]
- [REDACTED]
[REDACTED]
- [REDACTED]
[REDACTED]
[REDACTED]

[REDACTED] CHC:

- Remove requirement that patient must be ambulatory based on expanded approval for Elevidys.
- Require attestation that antibody titers are less than 1:400 to align with labeling.
- Require attestation that the patient's liver, platelet, and troponin-I levels have been assessed.

[REDACTED]

- [REDACTED]
[REDACTED]
- [REDACTED]
[REDACTED]
[REDACTED]

<p>RSV Vaccine</p>	<p>PerformRx makes the following recommendation:</p> <p>[REDACTED]</p> <ul style="list-style-type: none">[REDACTED][REDACTED] <p>[REDACTED]</p> <ul style="list-style-type: none">[REDACTED][REDACTED] <p>[REDACTED]</p> <ul style="list-style-type: none">[REDACTED][REDACTED] <p>[REDACTED]</p> <ul style="list-style-type: none">[REDACTED] <p>[REDACTED]</p> <ul style="list-style-type: none">[REDACTED][REDACTED][REDACTED][REDACTED][REDACTED]	<p>Committee approved as recommended:</p> <p>Motion: Robert Hockmuth Second: Tracey Davis</p>	<p>PerformRx will update the criteria and formulary/PDL with any changes</p>
--------------------	---	---	--

	<p>[REDACTED]</p> <ul style="list-style-type: none"> [REDACTED] <p>[REDACTED]</p> <ul style="list-style-type: none"> [REDACTED] <p>[REDACTED]</p> <p>CHC:</p> <ul style="list-style-type: none"> Add Capvaxive to the supplemental formulary with an age limit of 19 years and older and a quantity limit of 1 dose per lifetime. <p>[REDACTED]</p> <ul style="list-style-type: none"> [REDACTED] 		
Anti-CD19 CAR-T Immunotherapies	<p>PerformRx makes the following recommendation:</p> <p>[REDACTED]</p> <ul style="list-style-type: none"> [REDACTED] [REDACTED] [REDACTED] [REDACTED] [REDACTED] [REDACTED] 	<p>Committee approved as recommended:</p> <p>Motion: Robert Hockmuth Second: Tracey Davis</p>	<p>PerformRx will update the criteria and formulary/PDL with any changes</p>

	<p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <ul style="list-style-type: none">I [REDACTED]I [REDACTED][REDACTED][REDACTED][REDACTED]I [REDACTED][REDACTED][REDACTED][REDACTED][REDACTED] <p>[REDACTED] CHC:</p> <ul style="list-style-type: none">• Streamline prescriber restriction.• Add criteria for Chronic Lymphocytic Leukemia to align with expanded indication for Breyanzi.• Separate the various types of Non-Hodgkin's Lymphoma into different criteria sections and aligned with new indications for Breyanzi in Follicular Lymphoma and Small Lymphocytic Lymphoma. <p>[REDACTED]</p> <ul style="list-style-type: none">I [REDACTED][REDACTED][REDACTED]I [REDACTED][REDACTED][REDACTED][REDACTED][REDACTED]		
--	--	--	--

<div data-bbox="126 186 258 219" data-label="Text"><p>[REDACTED]</p></div>	<div data-bbox="682 151 1117 219" data-label="Text"><p>[REDACTED]</p></div> <div data-bbox="562 259 663 289" data-label="Text"><p>[REDACTED]</p></div> <div data-bbox="611 300 1236 443" data-label="List-Group"><ul style="list-style-type: none">[REDACTED][REDACTED][REDACTED]</div> <div data-bbox="562 483 663 513" data-label="Text"><p>[REDACTED]</p></div> <div data-bbox="611 524 1224 703" data-label="List-Group"><ul style="list-style-type: none">[REDACTED][REDACTED][REDACTED]</div> <div data-bbox="562 743 663 773" data-label="Text"><p>[REDACTED]</p></div> <div data-bbox="611 784 1211 927" data-label="List-Group"><ul style="list-style-type: none">[REDACTED][REDACTED]</div> <div data-bbox="562 967 663 997" data-label="Text"><p>[REDACTED]</p></div> <div data-bbox="611 1008 1140 1076" data-label="List-Group"><ul style="list-style-type: none">[REDACTED]</div>	<div data-bbox="1308 151 1612 219" data-label="Text"><p>[REDACTED]</p></div> <div data-bbox="1266 259 1621 328" data-label="Text"><p>[REDACTED]</p></div>	<div data-bbox="1707 151 1948 289" data-label="Text"><p>[REDACTED]</p></div>
7. Drug Reviews			
A. Therapeutic Class			
<div data-bbox="126 1323 512 1356" data-label="Text"><p>[REDACTED]</p></div>	<div data-bbox="682 1287 1117 1356" data-label="Text"><p>[REDACTED]</p></div>	<div data-bbox="1308 1287 1612 1356" data-label="Text"><p>[REDACTED]</p></div>	<div data-bbox="1707 1287 1948 1356" data-label="Text"><p>[REDACTED]</p></div>

	<ul style="list-style-type: none"> ■ [REDACTED] ■ [REDACTED] ■ [REDACTED] ■ [REDACTED] 		
Hepatitis B Vaccines.	<p>PerformRx makes the following recommendation:</p> <p>■ [REDACTED]</p> <ul style="list-style-type: none"> ■ [REDACTED] <p>■ [REDACTED]</p> <ul style="list-style-type: none"> ■ [REDACTED] <p>■ [REDACTED]</p> <ul style="list-style-type: none"> ■ [REDACTED] 	<p>Committee approved as recommended:</p> <p>Motion: Michael Baer Second: David Batluck</p>	<p>PerformRx will update the criteria and formulary/PDL with any changes</p>

	<p>██████████ ██████████</p> <p>██████████ CHC:</p> <ul style="list-style-type: none"> • Add Hecplisav-B to the supplemental formulary (T3) with an age limit minimum of 19 years and lifetime quantity limit of 2 doses per lifetime to increase access to vaccines. • Update the quantity limits to lifetime quantity limits for Prehevbrio (3 doses per lifetime), Engerix-B (4 doses per lifetime), and Recombivax HB (3 doses per lifetime). <p>██████████ ██████████</p>		
██████████ ██████████ ██████████ ██████████	<p>██████████ ██████████</p> <p>██████████ ██████████ ██████████ ██████████ ██████████</p> <p>██████████ ██████████ ██████████ ██████████</p> <p>██████████ ██████████ ██████████ ██████████</p> <p>██████████ ██████████</p>	██████████ ██████████ ██████████ ██████████	██████████ ██████████ ██████████ ██████████

	<ul style="list-style-type: none"> █ [REDACTED] █ [REDACTED] █ [REDACTED] █ [REDACTED] 	<ul style="list-style-type: none"> █ [REDACTED] 	
Chelating Agents	<p>PerformRx makes the following recommendation:</p> <ul style="list-style-type: none"> █ [REDACTED] <ul style="list-style-type: none"> █ [REDACTED] █ [REDACTED] █ [REDACTED] █ [REDACTED] █ [REDACTED] █ [REDACTED] █ [REDACTED] █ [REDACTED] █ [REDACTED] <ul style="list-style-type: none"> █ [REDACTED] █ [REDACTED] █ [REDACTED] █ [REDACTED] █ [REDACTED] <ul style="list-style-type: none"> █ [REDACTED] █ [REDACTED] █ [REDACTED] 	<p>Committee approved as recommended:</p> <p>Motion: Michael Baer Second: David Batluck</p> <p><i>Amendment:</i> *Michael Baer asked if the laboratory confirmed dx Wilson's disease required only one diagnosed test – criteria will be updated to spell out that only one test is required.</p>	<p>PerformRx will update the criteria and formulary/PDL with any changes</p>

	<ul style="list-style-type: none"> ■ [REDACTED] <p>CHC:</p> <ul style="list-style-type: none"> • No changes for these medications. • Approve the Chelating Agents prior authorization criteria: <ul style="list-style-type: none"> ○ Add requirement of confirmed testing for Wilson's disease. <p>[REDACTED]</p> <ul style="list-style-type: none"> ■ [REDACTED] ■ [REDACTED] ■ [REDACTED] ■ [REDACTED] 		
B. Single Products			
Duvyzat	<p>PerformRx makes the following recommendation:</p> <p>[REDACTED]</p> <ul style="list-style-type: none"> ■ [REDACTED] ■ [REDACTED] <p>[REDACTED]</p> <ul style="list-style-type: none"> ■ [REDACTED] ■ [REDACTED] 	<p>Committee approved as recommended:</p> <p>Motion: Don Cooper Second: Andrew Peterson</p> <p>*Chris Antypas asked if the generic Emflaza is on formularies and listed as an alternative?</p> <p>PerformRx will look into it for additional information.</p>	<p>PerformRx will update the criteria and formulary/PDL with any changes</p>

	<p>██████████</p> <ul style="list-style-type: none"> ██████████ ██████████ ██████████ ██████████ <p>██████████</p> <ul style="list-style-type: none"> ██████████ ██████████ ██████████ ██████████ <p>██████████ CHC:</p> <ul style="list-style-type: none"> • Add Duvyzat to Tier 4 with a prior authorization requirement. • Approve the newly developed Duvyzat prior authorization criteria. <p>██████████</p> <ul style="list-style-type: none"> ██████████ ██████████ ██████████ ██████████ 		
Beqvez	<p>PerformRx makes the following recommendation:</p> <p>██████████</p> <ul style="list-style-type: none"> ██████████ ██████████ ██████████ ██████████ 	<p>Committee approved as recommended:</p> <p>Motion: Don Cooper Second: Andrew Peterson</p>	<p>PerformRx will update the criteria and formulary/PDL with any changes</p>

	<p>[REDACTED]</p> <ul style="list-style-type: none"> [REDACTED] [REDACTED] <p>[REDACTED]</p> <ul style="list-style-type: none"> [REDACTED] <p>[REDACTED]</p> <ul style="list-style-type: none"> [REDACTED] [REDACTED] [REDACTED] <p>[REDACTED] CHC:</p> <ul style="list-style-type: none"> • Add Beqvez to Tier 4 with a prior authorization requirement. • Update the Gene Therapy for Hemophilia B prior authorization criteria. <p>[REDACTED]</p> <ul style="list-style-type: none"> [REDACTED] [REDACTED] 		
Voydeva	<p>PerformRx makes the following recommendation:</p> <p>[REDACTED]</p>	<p>Committee approved as recommended:</p> <p>Motion: Don Cooper Second: Andrew Peterson</p>	<p>PerformRx will update the criteria and formulary/PDL with any changes</p>

	<p>[REDACTED]</p> <p>[REDACTED]</p> <p>CHC:</p> <ul style="list-style-type: none"> • Add Voydeya to Tier 4 with a prior authorization requirement. • Update the Complement Inhibitors prior authorization criteria: <ul style="list-style-type: none"> ○ Add Voydeya (danicopan) to the drug list. ○ Add a Paroxysmal Nocturnal Hemoglobinuria (PNH) section to require Voydeya (danicopan) be used as add-on therapy per the package insert. <p>[REDACTED]</p> <ul style="list-style-type: none"> ■ [REDACTED] ■ [REDACTED] ■ [REDACTED] ■ [REDACTED] ■ [REDACTED] ■ [REDACTED] ■ [REDACTED] ■ [REDACTED] ■ [REDACTED] ■ [REDACTED] 		
Xolremdi	<p>PerformRx makes the following recommendation:</p> <p>[REDACTED]</p> <ul style="list-style-type: none"> ■ [REDACTED] <p>[REDACTED]</p>	<p>Committee approved as recommended:</p> <p>Motion: Don Cooper Second: Andrew Peterson</p>	<p>PerformRx will update the criteria and formulary/PDL with any changes</p>

█ [REDACTED]
[REDACTED]

[REDACTED]

█ [REDACTED]
[REDACTED]
█ [REDACTED]
[REDACTED]

[REDACTED]

█ [REDACTED]
[REDACTED]

[REDACTED]

█ [REDACTED]
[REDACTED]
█ [REDACTED]
[REDACTED]

[REDACTED]

█ [REDACTED]
[REDACTED]
█ [REDACTED]
[REDACTED]

[REDACTED] **CHC:**

- Add Xolremdi to T4 of the formulary with a prior authorization requirement.
- Approve the newly developed Xolremdi prior authorization criteria.

[REDACTED]

█ [REDACTED]
[REDACTED]

	<ul style="list-style-type: none"> █ [REDACTED] 		
Lenmeldy	<p>PerformRx makes the following recommendation:</p> <ul style="list-style-type: none"> █ [REDACTED] █ [REDACTED] █ [REDACTED] <p>[REDACTED]</p> <ul style="list-style-type: none"> █ [REDACTED] <p>[REDACTED]</p> <ul style="list-style-type: none"> █ [REDACTED] █ [REDACTED] █ [REDACTED] <p>[REDACTED]</p> <ul style="list-style-type: none"> █ [REDACTED] <p>[REDACTED]</p> <ul style="list-style-type: none"> █ [REDACTED] █ [REDACTED] █ [REDACTED] 	<p>Committee approved as recommended:</p> <p>Motion: Don Cooper Second: Andrew Peterson</p>	<p>PerformRx will update the criteria and formulary/PDL with any changes</p>

	<p>[REDACTED]</p> <ul style="list-style-type: none"> [REDACTED] [REDACTED] [REDACTED] <p>[REDACTED] CHC:</p> <ul style="list-style-type: none"> • Add Lenmeldy to Tier 4 with a prior authorization requirement. • Approve the newly developed Lenmeldy prior authorization criteria. <p>[REDACTED]</p> <ul style="list-style-type: none"> [REDACTED] [REDACTED] [REDACTED] 		
New Products			
	<p>PerformRx makes the following recommendation:</p> <p>[REDACTED]</p> <ul style="list-style-type: none"> [REDACTED] <p>Add to Specialty Tier 4 with drug specific PA for [REDACTED] CHC:</p> <ul style="list-style-type: none"> • Vioice <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p>	<p>Committee approved as recommended:</p> <p>Motion: Don Cooper Second: Michael Baer</p>	<p>PerformRx will update the criteria and formulary/PDL with any changes</p>

[illegible]

	<div><div>[REDACTED]</div><div><div>[REDACTED]</div><div>[REDACTED]</div><div>[REDACTED]</div><div>[REDACTED]</div></div><div><div>[REDACTED]</div><div>[REDACTED]</div><div><div>[REDACTED]</div><div>[REDACTED]</div><div>[REDACTED]</div><div>[REDACTED]</div><div>[REDACTED]</div></div></div></div>		
9. Prior Authorization Criteria Review			
A. Prior Authorization Annual Criteria			
<div><div>[REDACTED]</div><div>[REDACTED]</div></div>	<div><div>[REDACTED]</div><div>[REDACTED]</div><div><div>[REDACTED]</div><div>[REDACTED]</div><div>[REDACTED]</div><div>[REDACTED]</div><div>[REDACTED]</div><div>[REDACTED]</div><div>[REDACTED]</div><div>[REDACTED]</div><div>[REDACTED]</div><div>[REDACTED]</div><div>[REDACTED]</div></div></div>	<div><div>[REDACTED]</div><div>[REDACTED]</div></div>	<div><div>[REDACTED]</div></div>

	<div><div>[REDACTED]</div><div><div>■</div><div>[REDACTED]</div></div><div><div>■</div><div>[REDACTED]</div></div><div><div>■</div><div>[REDACTED]</div></div></div>		
	<div><div>[REDACTED]</div><div><div>■</div><div>[REDACTED]</div></div><div><div>■</div><div>[REDACTED]</div></div><div><div>■</div><div>[REDACTED]</div></div></div>		
	<div><div>[REDACTED]</div><div><div>■</div><div>[REDACTED]</div></div><div><div>■</div><div>[REDACTED]</div></div></div>		
	<div><div>PerformRx makes the following recommendation:</div></div>	<div><div>Committee approved as recommended:</div></div>	

BCMA Directed CAR T-Cell
Therapy.

[REDACTED]
[REDACTED]
[REDACTED]
[REDACTED]
[REDACTED]

[REDACTED]
[REDACTED]
[REDACTED]
[REDACTED]
[REDACTED]
[REDACTED]
[REDACTED]

[REDACTED]
[REDACTED]
[REDACTED]
[REDACTED]
[REDACTED]
[REDACTED]
[REDACTED]

[REDACTED]
[REDACTED]
[REDACTED]
[REDACTED]
[REDACTED]
[REDACTED]
[REDACTED]

[REDACTED]

Motion: Don Cooper
Second: Michael Baer

PerformRx will
update the criteria
and formulary/PDL
with any changes

	<ul style="list-style-type: none"> █ [REDACTED] █ [REDACTED] █ [REDACTED] <p>█ CHC:</p> <ul style="list-style-type: none"> • Update language for Abecma as it received an expanded indication for use after two lines of prior therapy. • Update language for Carvykti as it is now approved for use in patients who have received at least one prior line of therapy. <p>█</p> <ul style="list-style-type: none"> █ [REDACTED] █ [REDACTED] █ [REDACTED] █ [REDACTED] 		
Brineura	<p>PerformRx makes the following recommendation:</p> <p>█</p> <ul style="list-style-type: none"> █ [REDACTED] █ [REDACTED] █ [REDACTED] █ [REDACTED] █ [REDACTED] <p>█</p> <ul style="list-style-type: none"> █ [REDACTED] █ [REDACTED] 	<p>Committee approved as recommended:</p> <p>Motion: Don Cooper Second: Michael Baer</p>	<p>PerformRx will update the criteria and formulary/PDL with any changes</p>

	<div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div></div></div><div><div><div><div></div><div></div></div><div><div></div><div></div></div></div><div><div><div><div></</div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div>
--	--

	<p>█ [REDACTED] [REDACTED]</p> <p>█ CHC:</p> <ul style="list-style-type: none"> • Allow use of Livmarli in progressive familial intrahepatic cholestasis to align with expanded indication. • Allow use of Bylvay in Alagille Syndrome to align with expanded indication. <p>█ [REDACTED]</p> <p>█ [REDACTED] [REDACTED] [REDACTED]</p> <p>█ [REDACTED] [REDACTED]</p>		
Mucopolysaccharidosis II Agents (Elaprase).	<p>PerformRx makes the following recommendation:</p> <p>█ [REDACTED] █ [REDACTED] [REDACTED]</p> <p>█ [REDACTED] █ [REDACTED] [REDACTED]</p> <p>█ [REDACTED] █ [REDACTED] [REDACTED]</p>	<p>Committee approved as recommended:</p> <p>Motion: Don Cooper Second: Michael Baer</p>	<p>PerformRx will update the criteria and formulary/PDL with any changes</p>

	<p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED] CHC:</p> <ul style="list-style-type: none"> • Lessen prescriber restrictions as there are a wide variety of specialists that play a role in treatment. <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p>		
Pyruvate Kinase Activators	<p>PerformRx makes the following recommendation:</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p>	<p>Committee approved as recommended:</p> <p>Motion: Don Cooper Second: Michael Baer</p>	<p>PerformRx will update the criteria and formulary/PDL with any changes</p>

	<div><div></div><div></div><div></div><div></div><div></div></div> <div><div></div><div>CHC:</div><div><div>Remove splenectomy exclusion as the 2024 pyruvate kinase deficiency guidelines recommend Pyrukynd irrespective of whether or not a patient has had a splenectomy in the past.</div></div></div> <div><div></div><div></div><div></div></div>		
Rituximab	<div>PerformRx makes the following recommendation:</div> <div><div></div><div></div><div></div></div> <div><div></div><div></div><div></div></div> <div><div></div><div></div><div></div></div>	<div>Committee approved as recommended:</div> <div>Motion: Don Cooper</div> <div>Second: Michael Baer</div>	<div>PerformRx will update the criteria and formulary/PDL with any changes</div>

Committee approved as recommended:

Motion: Don Cooper
Second: Michael Baer

PerformRx will update the criteria and formulary/PDL with any changes

	<p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p>		
	<p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p>		
	<p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p>		
	<p>[REDACTED] CHC:</p> <ul style="list-style-type: none">Require documentation of a medical reason for not having a trial and failure, intolerance, or contraindication to Beyfortus (niresvimab) prior to using Synagis (palivizumab) as recommended in guidelines as it treats a broader population via a single dose versus a more narrow population via a multiple dose administration schedule.		

	<ul style="list-style-type: none"> Update the dosage requirement to documentation of the patient's weight to ensure appropriate dosing. 		
	<p>[REDACTED]</p> <ul style="list-style-type: none"> [REDACTED] [REDACTED] [REDACTED] [REDACTED] [REDACTED] [REDACTED] 		
[REDACTED]	<p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <ul style="list-style-type: none"> [REDACTED] [REDACTED] [REDACTED] [REDACTED] <p>[REDACTED]</p> <ul style="list-style-type: none"> [REDACTED] [REDACTED] [REDACTED] [REDACTED] <p>[REDACTED]</p> <ul style="list-style-type: none"> [REDACTED] [REDACTED] [REDACTED] [REDACTED] [REDACTED] [REDACTED] <p>[REDACTED]</p>	<p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p>	<p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p>

<div>[REDACTED]</div>	<div>[REDACTED]</div>	<div>[REDACTED]</div>	<div>[REDACTED]</div>
<div>B. Prior Authorization Criteria Annual Review without Clinical Changes:</div>			
<div>[REDACTED]</div>	<div>[REDACTED]</div>	<div>[REDACTED]</div>	<div>[REDACTED]</div>

	<p>[REDACTED]</p> <ul style="list-style-type: none"> [REDACTED] <p>[REDACTED]</p> <ul style="list-style-type: none"> [REDACTED] <p>[REDACTED]</p> <ul style="list-style-type: none"> [REDACTED] 		
<p>Anti-FGF23 Monoclonal Antibodies. 464</p>	<p>PerformRx makes the following recommendation:</p> <p>[REDACTED]</p> <ul style="list-style-type: none"> [REDACTED] <p>[REDACTED]</p> <ul style="list-style-type: none"> [REDACTED] <p>[REDACTED]</p> <ul style="list-style-type: none"> [REDACTED] 	<p>Committee approved as recommended:</p> <p>Motion: Don Cooper Second: Michael Baer</p>	<p>No Changes</p>

	<div><div>[REDACTED]</div><div><div>[REDACTED]</div><div>[REDACTED]</div><div>[REDACTED]</div></div><div><div>[REDACTED]</div><div><div>[REDACTED]</div><div>[REDACTED]</div><div>[REDACTED]</div></div><div><div>[REDACTED]</div><div><div>[REDACTED]</div><div>[REDACTED]</div><div>[REDACTED]</div></div><div><div>[REDACTED] CHC:</div><div><ul style="list-style-type: none">• Approve the Anti-FGF23 Monoclonal Antibodies prior authorization criteria with no clinical changes.</div></div><div><div>[REDACTED]</div><div><div>[REDACTED]</div><div>[REDACTED]</div><div>[REDACTED]</div></div></div></div></div></div>		
<div><div>[REDACTED]</div><div>[REDACTED]</div><div>[REDACTED]</div></div>	<div><div>[REDACTED]</div><div>[REDACTED]</div><div><div>[REDACTED]</div><div>[REDACTED]</div><div>[REDACTED]</div><div>[REDACTED]</div><div>[REDACTED]</div></div></div>	<div><div>[REDACTED]</div><div>[REDACTED]</div><div>[REDACTED]</div><div>[REDACTED]</div></div>	<div><div>[REDACTED]</div></div>

<p>Camzyos</p>	<p>PerformRx makes the following recommendation:</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED] CHC:</p> <ul style="list-style-type: none"> • Approve the Camzyos prior authorization criteria with no clinical changes. <p>[REDACTED]</p> <p>[REDACTED]</p>	<p>Committee approved as recommended:</p> <p>Motion: Don Cooper Second: Michael Baer</p>	<p>No Changes</p>
<p>[REDACTED]</p>	<p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p>	<p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p>	<p>[REDACTED]</p>

<p>[REDACTED]</p>	<p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p>	<p>[REDACTED]</p> <p>[REDACTED]</p>	
<p>Daybue</p>	<p>PerformRx makes the following recommendation:</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p>	<p>Committee approved as recommended:</p> <p>Motion: Don Cooper Second: Michael Baer</p>	<p>No Changes</p>

	<div data-bbox="598 146 1239 259"><div data-bbox="598 146 630 186">■</div><div data-bbox="651 146 1239 259"></div></div> <div data-bbox="556 292 1239 446"><div data-bbox="556 292 661 332"></div><div data-bbox="598 332 1239 446"><div data-bbox="598 332 630 373">■</div><div data-bbox="651 332 1239 446"></div></div></div> <div data-bbox="556 446 1239 592"><div data-bbox="556 446 661 487"></div><div data-bbox="598 487 1239 592"><div data-bbox="598 487 630 527">■</div><div data-bbox="651 487 1239 592"></div></div></div> <div data-bbox="556 625 1239 779"><div data-bbox="556 625 661 665"></div><div data-bbox="598 665 1239 779"><div data-bbox="598 665 630 706">■</div><div data-bbox="651 665 1239 779"></div></div></div> <div data-bbox="556 812 1239 966"><div data-bbox="556 812 661 852"></div><div data-bbox="598 852 1239 966"><div data-bbox="598 852 630 893">■</div><div data-bbox="651 852 1239 966"></div></div></div> <div data-bbox="556 990 1239 1144"><div data-bbox="556 990 693 1031"></div><div data-bbox="682 990 787 1031">CHC:</div><div data-bbox="598 1031 1239 1144"><ul style="list-style-type: none">• Approve the Enzyme Replacement Therapies for Fabry Disease prior authorization criteria with no clinical changes.</div></div> <div data-bbox="556 1144 1239 1299"><div data-bbox="556 1144 661 1185"></div><div data-bbox="598 1185 1239 1299"><div data-bbox="598 1185 630 1226">■</div><div data-bbox="651 1185 1239 1299"></div></div></div>	<div data-bbox="1249 129 1669 178">Second: Michael Baer</div>	
--	---	--	--

Fecal Microbiota	<p>PerformRx makes the following recommendation:</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED] CHC:</p> <ul style="list-style-type: none"> • Approve the Fecal Microbiota prior authorization criteria with no changes. <p>[REDACTED]</p> <p>[REDACTED]</p>	<p>Committee approved as recommended:</p> <p>Motion: Don Cooper Second: Michael Baer</p>	No Changes
Increlex	<p>PerformRx makes the following recommendation:</p>	<p>Committee approved as recommended:</p>	

	<p>█ [REDACTED] [REDACTED] [REDACTED] [REDACTED]</p> <p>█ [REDACTED] [REDACTED] [REDACTED] [REDACTED]</p> <p>█ [REDACTED] [REDACTED] [REDACTED] [REDACTED]</p> <p>█ CHC:</p> <ul style="list-style-type: none"> • Approve the Insulin-Like Growth Factor-1 Receptor (Igf-1r) Antagonists For Thyroid Eye Disease prior authorization criteria with no changes. <p>█ [REDACTED] [REDACTED] [REDACTED] [REDACTED]</p>		
Joenja	<p>PerformRx makes the following recommendation:</p> <p>█ [REDACTED] [REDACTED] [REDACTED]</p>	<p>Committee approved as recommended:</p> <p>Motion: Don Cooper Second: Michael Baer</p>	No Changes

	<div><div></div><div></div><div></div><div></div><div>CHC:</div><div><ul style="list-style-type: none">Approve the Joenja prior authorization criteria with no changes.</div><div></div></div>		
<div></div>	<div><div></div><div></div><div></div><div></div><div></div><div></div><div></div></div>	<div><div></div><div></div><div></div><div></div></div>	<div></div>

	<ul style="list-style-type: none"> <ul style="list-style-type: none"> [REDACTED] [REDACTED] <ul style="list-style-type: none"> [REDACTED] [REDACTED] <ul style="list-style-type: none"> [REDACTED] [REDACTED] <ul style="list-style-type: none"> [REDACTED] [REDACTED] 		
Omisirge	<p>PerformRx makes the following recommendation:</p> <ul style="list-style-type: none"> <ul style="list-style-type: none"> [REDACTED] [REDACTED] <ul style="list-style-type: none"> [REDACTED] [REDACTED] <ul style="list-style-type: none"> [REDACTED] [REDACTED] <ul style="list-style-type: none"> [REDACTED] [REDACTED] 	<p>Committee approved as recommended:</p> <p>Motion: Don Cooper Second: Michael Baer</p>	No Changes

	<p>CHC:</p> <ul style="list-style-type: none"> • Approve the Omisirge prior authorization criteria with no clinical changes. <p>[REDACTED]</p> <p>[REDACTED]</p>		
[REDACTED]	<p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p>	<p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p>	[REDACTED]
Qalsody	<p>PerformRx makes the following recommendation:</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p>	<p>Committee approved as recommended:</p> <p>Motion: Don Cooper</p> <p>Second: Michael Baer</p>	No Changes

	<div><div></div><div></div><div></div></div> <div><div>CHC:</div><div><div>• Approve the Skyclarys (omaveloxolone) prior authorization criteria.</div><div>• Add documentation of the modified FARS score ≥ 20 and ≤ 80 to align with the Enterprise criteria.</div></div></div> <div><div></div><div></div></div>		
<div></div>	<div><div></div><div></div><div></div><div></div><div></div><div></div><div></div></div>	<div><div></div><div></div><div></div><div></div></div>	<div></div>
<div></div>	<div><div></div><div></div><div></div><div></div><div></div><div></div><div></div></div>	<div><div></div><div></div><div></div><div></div></div>	<div></div>

	<ul style="list-style-type: none"> <ul style="list-style-type: none"> [REDACTED] [REDACTED] [REDACTED] [REDACTED] <ul style="list-style-type: none"> [REDACTED] [REDACTED] [REDACTED] 		
Verquvo	<p>PerformRx makes the following recommendation:</p> <ul style="list-style-type: none"> [REDACTED] <ul style="list-style-type: none"> [REDACTED] [REDACTED] [REDACTED] <ul style="list-style-type: none"> [REDACTED] [REDACTED] [REDACTED] <ul style="list-style-type: none"> [REDACTED] [REDACTED] <p>[REDACTED] CHC:</p> <ul style="list-style-type: none"> <ul style="list-style-type: none"> Approve the Verquvo prior authorization criteria with no clinical changes. <ul style="list-style-type: none"> [REDACTED] <ul style="list-style-type: none"> [REDACTED] [REDACTED] 	<p>Committee approved as recommended:</p> <p>Motion: Don Cooper Second: Michael Baer</p>	No Changes

<p>Vijoice</p>	<p>PerformRx makes the following recommendation:</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED] CHC:</p> <ul style="list-style-type: none"> • Approve the Verquvo prior authorization criteria with no clinical changes. <p>[REDACTED]</p> <p>[REDACTED]</p>	<p>Committee approved as recommended:</p> <p>Motion: Don Cooper Second: Michael Baer</p>	<p>No Changes</p>
<p>[REDACTED]</p>	<p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p>	<p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p>	<p>[REDACTED]</p>

10. Recalls	4/18/2024 – 7/17/2024 There were no Class 1 or 2 recalls impacting all lots for medications listed within Medispan	Informational	PerformRx
11. Adjournment	The meeting adjourned at 7:18 PM EST		Jeffrey Kreitman
	The next meeting November 4th, 202 6:00 PM- 8:00		

Jeffrey Kreitman PharmD

11/5/2024
Date